Maxim Group Remains a Buy on Yield10 Bioscience Inc (YTEN)

By Jason Carr

Maxim Group analyst Anthony Vendetti maintained a Buy rating on Yield10 Bioscience Inc (YTENResearch Report) yesterday and set a price target of $3. The company’s shares closed yesterday at $0.80, close to its 52-week low of $0.68.

Vendetti observed:

“In our opinion, the research pipeline for YTEN remains robust; we anticipate increased canola seed and oil content to be a pathway to commercialization.”

According to TipRanks.com, Vendetti is a 3-star analyst with an average return of 1.8% and a 45.2% success rate. Vendetti covers the Healthcare sector, focusing on stocks such as Restoration Robotics Inc, Xtant Medical Holdings, and Ra Medical Systems Inc.

Currently, the analyst consensus on Yield10 Bioscience Inc is a Moderate Buy with an average price target of $3.

See today’s analyst top recommended stocks >>

The company has a one-year high of $1.85 and a one-year low of $0.68. Currently, Yield10 Bioscience Inc has an average volume of 192.4K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Yield10 Bioscience, Inc. is an agricultural bioscience company, which focuses on the development of technologies to produce step-change improvements in crop yield for food and feed crops to enhance global food security. The company was founded by Anthony J. Sinskey, Simon F. Williams and Oliver P. Peoples in June 1992 and is headquartered in Woburn, MA.